Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 14, Issue 3, Pages 206-218
Publisher
Springer Nature
Online
2011-05-17
DOI
10.1038/pcan.2011.24
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.
- (2011) Marianne D. Sadar CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
- (2010) L R Molife et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
- (2010) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
- (2010) D. C. Talbot et al. CLINICAL CANCER RESEARCH
- Figitumumab (CP-751,871) for cancer therapy
- (2010) Antonio Gualberto EXPERT OPINION ON BIOLOGICAL THERAPY
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Temporal Trends in Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer
- (2010) Gregory T. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
- (2009) Primo N. Lara et al. ANTI-CANCER DRUGS
- Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
- (2009) Jeanny B. Aragon-Ching et al. BJU INTERNATIONAL
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
- (2009) W. Zhang et al. CANCER RESEARCH
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Survivin: A new target for anti-cancer therapy
- (2009) Bríd M. Ryan et al. CANCER TREATMENT REVIEWS
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
- (2009) T. Satoh et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models
- (2009) Claudio Festuccia et al. ENDOCRINE-RELATED CANCER
- DNA methylation changes in prostate cancer: current developments and future clinical implementation
- (2009) Mohammad Obaidul Hoque EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
- (2009) Prateek Mendiratta et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Src in Solid Tumors
- (2009) D. L. Wheeler et al. ONCOLOGIST
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
- (2009) Per Björk et al. PLOS BIOLOGY
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Src signaling in metastatic bone disease
- (2008) John Araujo et al. INTERNATIONAL JOURNAL OF CANCER
- In Reply
- (2008) Tomasz M. Beer JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
- (2008) A. Dubrovska et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search